

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**SciClone Pharmaceuticals (Holdings) Limited**

賽生藥業控股有限公司\*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6600)

**POLL RESULTS OF THE ANNUAL GENERAL MEETING  
HELD ON THURSDAY, MAY 25, 2023  
AND  
APPOINTMENT OF EXECUTIVE DIRECTOR**

Reference is made to the circular (the “Circular”) of SciClone Pharmaceuticals (Holdings) Limited (the “Company”) incorporating, amongst others, the notice (the “Notice”) of the annual general meeting of the Company (the “AGM”), dated April 28, 2023, and the supplemental announcement to the Circular dated May 9, 2023. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

**POLL RESULTS OF THE AGM**

At the AGM held on Thursday, May 25, 2023, all the proposed resolutions as set out in the Notice were taken by poll. The poll results are as follows:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive, consider and adopt the audited consolidated financial statements and the reports of the directors and auditors for the year ended December 31, 2022.	220,491,796 (99.99%)	500 (0.01%)
2.	To declare a final dividend of HK\$0.39 per ordinary share for the year ended December 31, 2022.	220,491,796 (99.99%)	500 (0.01%)

Ordinary Resolutions		Number of Votes (%)	
		For	Against
3(a).	To elect Ms. Pan Rongrong as an executive director of the Company.	220,491,796 (99.99%)	500 (0.01%)
3(b).	To re-elect Mr. Li Zhenfu as a non-executive director of the Company.	212,288,246 (96.28%)	8,204,050 (3.72%)
3(c).	To re-elect Mr. Shi Cen as a non-executive director of the Company.	N/A <sup>Note (j)</sup>	N/A <sup>Note (j)</sup>
3(d).	To re-elect Mr. Gu Alex Yushao as an independent non-executive director of the Company.	220,491,796 (99.99%)	500 (0.01%)
3(e).	To re-elect Ms. Wendy Hayes as an independent non-executive director of the Company.	210,786,614 (95.60%)	9,705,682 (4.40%)
3(f).	To authorize the board of directors to fix the respective directors' remuneration.	220,491,796 (99.99%)	500 (0.01%)
4.	To re-appoint PricewaterhouseCoopers as the auditor and to authorize the board of directors to fix its remuneration.	218,990,164 (99.32%)	1,502,132 (0.68%)
5.	To give a general mandate to the directors to repurchase shares of the Company not exceeding 10% of the total number of issued shares of the Company as at the date of passing of this resolution.	220,491,796 (99.99%)	500 (0.01%)
6.	To give a general mandate to the directors to issue, allot and deal with additional shares of the Company not exceeding 20% of the total number of issued shares of the Company as at the date of passing of this resolution.	207,087,250 (93.92%)	13,405,046 (6.08%)
7.	To extend the general mandate granted to the directors to issue, allot and deal with additional shares in the capital of the Company by the aggregate number of the shares repurchased by the Company.	207,160,250 (93.95%)	13,332,046 (6.05%)

Special Resolution		Number of Votes (%)	
		For	Against
8.	To approve the proposed amendments to the existing amended and restated articles of association of the Company and to adopt the second amended and restated articles of association of the Company in substitution for and to the exclusion of the existing amended and restated articles of association of the Company, as set out in the notice convening the AGM dated April 28, 2023.	218,881,109 (99.27%)	1,611,187 (0.73%)

*Notes:*

- (a) As a majority of the votes were cast in favour of each of the resolutions numbered 1 to 7 (except the resolution numbered 3(c)), all these resolutions were duly passed as ordinary resolutions.
- (b) As more than three-fourths of the votes were cast in favour of the resolution numbered 8, the resolution was duly passed as a special resolution.
- (c) As at the date of the AGM, the total number of shares of the Company in issue was 618,295,072.
- (d) The total number of shares of the Company entitling the holder to attend and vote on the resolutions at the AGM was 618,295,072.
- (e) There were no shares entitling the holder to attend and abstain from voting in favour of the resolutions at the AGM as set out in rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).
- (f) No shareholder of the Company was required under the Listing Rules to abstain from voting on the resolutions at the AGM.
- (g) None of the shareholders of the Company have stated their intention in the Company’s circular dated April 28, 2023 to vote against or to abstain from voting on any of the resolutions at the AGM.
- (h) The Company’s branch share registrar, Tricor Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.
- (i) All directors of the Company attended the AGM.
- (j) Reference is made to the announcement of the Company dated May 22, 2023, pursuant to which the Company announced that Mr. Shi Cen would retire from office at the AGM and did not offer himself for re-election at the AGM (the “**Retirement**”). Due to the Retirement, Mr. Shi Cen retired as a non-executive Director at the AGM and the above resolution No. 3(c) was no longer applicable and was not put forward for consideration at the AGM.

## APPOINTMENT OF EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) is pleased to announce that, as a majority of the votes were cast by the Shareholders in favour of, among others, the resolution numbered 3(a), Ms. Pan Rongrong (“**Ms. Pan**”) has been appointed as an executive Director for a term of three years with effect from the conclusion of the AGM. Please see below biographical details of Ms. Pan.

### **Ms. Pan Rongrong**

Ms. Pan Rongrong, aged 45, is an executive Director, the vice president, chief financial officer, and joint company secretary of the Company. Prior to joining our Group in November 2018, Ms. Pan worked at PricewaterhouseCoopers Zhong Tian CPAs Limited Company (普華永道中天會計師事務所有限公司) from July 2002 to November 2018 with last position as a partner, and served as an associate of auditing department of Arthur Andersen LLP (安達信華強會計師事務所) from August 2001 to June 2002. Ms. Pan has served as an independent non-executive Director and chairwoman of the Audit Committee of Yidu Tech Inc. (Hong Kong Stock Exchange: 2158) (醫渡科技有限公司) since January 2021.

Ms. Pan obtained her bachelor’s degree in economics from Shanghai International Studies University (上海外國語大學) in July 1998 in Shanghai, the PRC, and her master’s degree in accounting from Fudan University (復旦大學) in July 2001 in Shanghai, the PRC. She is a member of China Certified Public Accountant Association.

Save as disclosed above, Ms. Pan has not been a director of any listed company in Hong Kong or overseas in the last three years and does not hold any other position with the Company and its subsidiaries. She does not have any relationship with any Directors, senior management or substantial or controlling shareholders of the Company.

Ms. Pan has entered into a director service contract with the Company for a period of three years with effect from the date of the AGM, pursuant to which Ms. Pan is entitled to receive an annual salary of RMB3,687,000 subject to revision as determined by the remuneration committee of the Company with reference to the operation results of the Group and the performance of Directors. The service contract may be terminated by not less than three months’ notice in writing served by either party on the other. Ms. Pan is subject to retirement and re-election at the AGM of the Company in accordance with the Articles of Association.

In accordance with the meaning of Part XV of the SFO, as at the date of this announcement, Ms. Pan was deemed to be interested in 3,825,000 Shares representing approximately 0.62% of the Shares issued by the Company. Save as disclosed above, Ms. Pan was not interested or deemed to be interested in any Shares or underlying shares of the Company or its associated corporations pursuant to Part XV of the SFO.

Save as disclosed herein, as at the date of this announcement, there were no other matters relating to the appointment of Ms. Pan that need to be brought to the attention of the Shareholders nor was there any information to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board wishes to express its warm welcome to Ms. Pan for joining the Board.

By Order of the Board  
**SciClone Pharmaceuticals (Holdings) Limited**  
**ZHAO Hong**  
*Executive Director, Chief Executive Officer and  
President*

Hong Kong, May 25, 2023

*As at the date of this announcement, the Board comprises Mr. Zhao Hong and Ms. Pan Rongrong as executive directors, Mr. Li Zhenfu, Dr. Daniel Luzius Vasella, Ms. Lin Shirley Yi-Hsien, and Ms. Wang Haixia as non-executive directors, and Dr. Liu Guoen, Dr. Chen Ping, Mr. Gu Alex Yushao and Ms. Wendy Hayes as independent non-executive directors.*

\* *For identification purpose only*